RxDoctor Payments Data

Jung Bae, MD

Internal Medicine · Los Angeles, CANPI 1124119805

Payments from drug & device makers

$2,445in general payments, 2019–2025

Across 105 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$700
  • AstraZeneca$238
  • Bayer$211
  • Lilly USA, LLC$183
  • Boehringer Ingelheim$168
  • Amarin Pharma, Inc.$151
  • plus $793 from 16 others

What the payments were for

  • Food & beverage$2,42599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,445 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$194,310
Medicare patients
239
Services billed
3,576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase466$364,135
VascepaIcosapent Ethyl880$222,658
JanumetSitagliptin Phos/Metformin Hcl308$216,289
JardianceEmpagliflozin282$200,754
LinzessLinaclotide329$197,359
TradjentaLinagliptin207$129,282
JanuviaSitagliptin Phosphate146$116,991
JentaduetoLinagliptin/Metformin Hcl124$76,793
XareltoRivaroxaban108$76,068
Memantine Hcl ErMemantine Hcl540$70,848
MyrbetriqMirabegron130$65,695
TrulicityDulaglutide58$65,146
EliquisApixaban80$50,646
FarxigaDapagliflozin Propanediol47$31,499
KerendiaFinerenone41$29,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis$700$587,798837 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Combivent Respimat, Jentadueto Xr$168$454,167706 claims
MerckJanumet, Januvia, Janumet Xr$115$352,756483 claims
Johnson & JohnsonXarelto$12$76,068108 claims
Lilly USA, LLCTrulicity$183$65,14658 claims
PfizerEliquis$74$50,64680 claims
AstraZenecaFarxiga, Symbicort$238$39,02981 claims
BayerKerendia$211$29,80641 claims
Sumitomo Pharma America, Inc.Gemtesa$57$26,19353 claims
Aimmune Therapeutics, Inc.Zenpep$28$21,53321 claims
Novo NordiskOzempic$89$20,20822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →